Trinity Biotech Added to Membership of Russell Global Index
June 26 2012 - 12:02PM
Trinity Biotech plc (Nasdaq:TRIB), a leading developer and
manufacturer of diagnostic products for the point-of-care and
clinical laboratory markets, today announced it has been added as a
member of the Russell Global Index as Russell Investments
reconstituted its comprehensive family of global indexes as of the
close of the equity markets on Friday, June 22, 2012.
Membership in the Russell Global Index, which remains in place
for one year, means automatic inclusion in the appropriate
large-cap, small-cap, all-cap indexes as well as the applicable
style, sector and country indexes. Russell determines membership
for its equity indexes primarily by objective,
market-capitalization rankings and style attributes.
Ronan O'Caoimh, CEO of Trinity Biotech, commented, "We are
pleased to have been added to the Russell Global Index. This speaks
to the continued growth of our Company and we look forward with
great anticipation to continuing to execute on our strategic
plan."
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for both
passive and active investment strategies. In the institutional
marketplace, an industry-leading $3.9 trillion in assets currently
are benchmarked to them.
The Russell Global Index, which captures approximately 98% of
investable securities globally, is reconstituted annually and all
sub-indexes are recalibrated simultaneously to accurately measure
current market realities for each market segment. These investment
tools originated from Russell's multi-manager investment business
in the early 1980s when the company saw the need for a more
objective, market-driven set of benchmarks in order to evaluate
outside investment managers.
Russell launched the Russell Global Index in 2007, leveraging
the popular methodology from its U.S. indexes. The broad-market
Russell 3000Ò Index serves as the U.S. component to the Russell
Global Index.
Total returns data for the Russell Global Index and other
Russell Indexes is available at
http://www.russell.com/indexes/data/Global_Equity/russell_global_returns.asp.
About Russell
Russell Investments (Russell) is a global asset manager and one
of only a few firms that offers actively managed, multi-asset
portfolios and services that include advice, investments and
implementation. Working with institutional investors, financial
advisors and individuals, Russell's core capabilities extend across
capital markets insights, manager research, Indexes, portfolio
implementation and portfolio construction. Russell has
approximately $155 billion in assets under management (as of
3/31/2012) and works with 2,400 institutional clients, more than
580 independent distribution partners and advisors, and individual
investors globally. Founded in 1936, Russell is a subsidiary of The
Northwestern Mutual Life Insurance Company.
About Trinity Biotech
Trinity Biotech develops, acquires, manufactures and markets
diagnostic systems, including both reagents and instrumentation,
for the point-of-care and clinical laboratory segments of the
diagnostic market. The products are used to detect infectious
diseases and to quantify the level of Haemoglobin A1c and other
chemistry parameters in serum, plasma and whole blood. Trinity
Biotech sells direct in the United States, Germany, France and the
U.K. and through a network of international distributors and
strategic partners in over 75 countries worldwide. For further
information please see the Company's website:
www.trinitybiotech.com.
The Trinity Biotech plc logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=10602
Forward-looking statements in this release are made pursuant to
the "safe harbor" provision of the Private Securities Litigation
Reform Act of 1995. Investors are cautioned that such
forward-looking statements involve risks and uncertainties
including, but not limited to, the results of research and
development efforts, the effect of regulation by the United States
Food and Drug Administration and other agencies, the impact of
competitive products, product development commercialisation and
technological difficulties, and other risks detailed in the
Company's periodic reports filed with the Securities and Exchange
Commission.
CONTACT: Trinity Biotech plc
Kevin Tansley
(353)-1-2769800
E-mail: kevin.tansley@trinitybiotech.com
Lytham Partners LLC
Joe Diaz, Joe Dorame & Robert Blum
602-889-9700
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Trinity Biotech (NASDAQ:TRIB)
Historical Stock Chart
From Apr 2023 to Apr 2024